# Lipidio Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lipidio-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.lipidiopharma.com
- Total disclosed funding: $20M
- Latest round: Series A (Nov 10, 2022)
- Investors on record: 2

## About

Lipidio Pharmaceuticals Inc. develops innovative pharmaceutical products that utilize the skin's endocrine functions to tackle obesity, offering effective solutions to individuals and healthcare providers alike.Founded in 2020 and headquartered in San Diego, US, Lipidio Pharmaceuticals Inc. specializes in leveraging skin signaling mechanisms to create pharmaceutical products aimed at obesity management. The company has successfully completed 2 funding deals, with its latest Series A round in November 2022 raising USD 20.00 mn from investors including 3E Bioventures Capital and Alethea Capital Management. The firm was founded by Raksha Shah, who leads the company alongside CEO J Foulkes.Lipidio Pharma focuses on developing innovative pharmaceutical products that leverage the skin as an endocrine organ to address obesity. Their flagship product utilizes skin signaling mechanisms to promote systemic health benefits, including significant reductions in weight and total body fat, targeting diverse patient populations struggling with obesity. The company aims to provide solutions for markets within the United States, Europe, and select regions in Asia, addressing the critical public health challenge posed by the obesity epidemic.Lipidio Pharma generates revenue through partnerships with healthcare institutions and pharmaceutical distributors. Its business model includes direct sales to healthcare providers and agreements with wholesalers for market distribution. Revenue transactions are based on the sale of its core therapeutic offerings, positioned to provide comprehensive solutions to obesity management.In November 2022, Lipidio Pharmaceuticals Inc. raised USD 20.00 mn in Series A funding, which will be utilized to support its clinical trials. The company is focused on developing new products aimed at enhancing obesity management and plans for expansion into additional markets in Europe and Asia by 2024. These strategic initiatives are intended to broaden their reach and improve product deployment in response to the growing obesity epidemic.

## Funding rounds

- Series A, Nov 10, 2022, $20M — Alethea Capital Management, 3E Bioventures Capital

## Investors

- Alethea Capital Management (https://capitalatlas.ai/funds/alethea-capital-management) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A